This is NOT an approval, it is the beginning of the approval process but only for two uses or indications... previously treated mantle cell lymphoma (MCL) and previously treated chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
online.wsj.com/article/PR-C...
Another step forward in the approval process...
Long-Term Ibrutinib Therapy Reverses CD8+ T Cell Exhaustion in B Cell CLLVenetoclax plus obinutuzumab - the first chemotherapy-free, fixed-duration first line CLL treatment approved by Health Canada
FDA Frontline Approval of Venetoclax and Obinituzumab in the USA
V + O frontline approved by FDA
BRUIN Study: phase 1/2 study of Pirtobrutinib (formerly Loxo 305) in relapsed or refractory B-cell malignancies 
